This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2016 by Juan A. Arnaiz, Hospital Clinic of Barcelona
Information provided by (Responsible Party):
Juan A. Arnaiz, Hospital Clinic of Barcelona Identifier:
First received: January 9, 2015
Last updated: October 19, 2016
Last verified: June 2016
There are few randomized clinical trials in advanced HIV patients. This is a multicenter, randomized, open clinical trial, comparing 2 parallel groups, to compare the immunological reconstitution and the virological efficacy and safety of 2 different combinations of antiretroviral therapy given once a day (QD): abacavir plus lamivudine plus either dolutegravir, or darunavir-ritonavir during 96 weeks in advanced antiretroviral naïve HIV-1 infected patients with less than 100 CD4+ T-cells/mm3. Primary endpoint is the median increase in CD4+ T-cell count at 48 weeks after starting HAART.

Condition Intervention Phase
Acquired Immune Deficiency Syndrome Virus Drug: Dolutegravir Drug: Darunavir/r Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial).

Resource links provided by NLM:

Further study details as provided by Juan A. Arnaiz, Hospital Clinic of Barcelona:

Primary Outcome Measures:
  • Median CD4 T cell count increase [ Time Frame: 48 weeks ]

Estimated Enrollment: 108
Study Start Date: April 2015
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: ABC+3TC+DTG
Abacavir+lamivudine+Dolutegravir, QD, Single tablet Regimen
Drug: Dolutegravir
Active Comparator: ABC+3TC+DRV/r
Abacavir+lamivudine+ritonavir-boosted darunavir, QD
Drug: Darunavir/r
Other Name: Ritonavir-boosted Darunavir


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. HIV patients > 18 years old who provide signed and dated informed consent.
  2. Male and female.
  3. Chronic HIV infection.
  4. Antiretroviral naïve.
  5. Confirmed CD4+ T cell count below 100 cells/mm3
  6. HLA B5701 negative patients.

Exclusion Criteria:

  1. Active opportunistic infections requiring parenteral treatment
  2. Patients with cryptococcal meningitis treated with voriconazole
  3. AIDS-defining cancers needing chemotherapy.
  4. Female patients pregnant or breastfeeding.
  5. Patients with documented history of allergy to sulfonamides.
  6. Any contraindications to study drugs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02337322

Contact: Jose Miro, MD, PhD +34932775586

Hospital Clinic of Barcelona Recruiting
Barcelona, BCN, Spain, 08013
Contact: Jose Miro, PhD    +34932275586   
Sponsors and Collaborators
Juan A. Arnaiz
  More Information

Responsible Party: Juan A. Arnaiz, MD, PhD, Hospital Clinic of Barcelona Identifier: NCT02337322     History of Changes
Other Study ID Numbers: Advanz-4
Study First Received: January 9, 2015
Last Updated: October 19, 2016

Keywords provided by Juan A. Arnaiz, Hospital Clinic of Barcelona:
Acquired Immune Deficiency Syndrome Virus
Antiretroviral treatment
HIV Advanced Disease

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
HIV Integrase Inhibitors
Integrase Inhibitors processed this record on June 23, 2017